Surface modification of titanium by anodic oxidation in phosphoric acid at low potentials. Part 2. In vitro and in vivo study

2013 ◽  
Vol 45 (9) ◽  
pp. 1395-1401 ◽  
Author(s):  
A. Gomez Sanchez ◽  
W. Schreiner ◽  
J. Ballarre ◽  
A. Cisilino ◽  
G. Duffó ◽  
...  
Nanoscale ◽  
2015 ◽  
Vol 7 (21) ◽  
pp. 9908-9918 ◽  
Author(s):  
Elisabeth Rieger ◽  
Agnès Dupret-Bories ◽  
Laetitia Salou ◽  
Marie-Helene Metz-Boutigue ◽  
Pierre Layrolle ◽  
...  

Nanoscale surface modification of titanium microbeads can control the soft tissue response in vitro and in vivo.


2017 ◽  
Vol 22 (6) ◽  
pp. 893-918 ◽  
Author(s):  
Balaram Das ◽  
Satyajit Tripathy ◽  
Jaydeep Adhikary ◽  
Sourav Chattopadhyay ◽  
Debasis Mandal ◽  
...  

2012 ◽  
Vol 24 (1) ◽  
pp. 161-169 ◽  
Author(s):  
A. Gomez Sanchez ◽  
J. Ballarre ◽  
J. C. Orellano ◽  
G. Duffó ◽  
S. Ceré

2016 ◽  
Vol 4 (1) ◽  
pp. 145-158 ◽  
Author(s):  
Michelle F. Griffin ◽  
Robert G. Palgrave ◽  
Alexander M. Seifalian ◽  
Peter E. Butler ◽  
Deepak M. Kalaskar

Enhancing tissue integration and angiogenesis of a novel nanocomposite polymer using plasma surface modification, an in vitro and in vivo study.


2020 ◽  
Vol 21 (15) ◽  
pp. 1688-1698
Author(s):  
Germeen N.S. Girgis

Purpose: The work was performed to investigate the feasibility of preparing ocular inserts loaded with Poly-ε-Caprolactone (PCL) nanoparticles as a sustained ocular delivery system. Methods: First, Atorvastatin Calcium-Poly-ε-Caprolactone (ATC-PCL) nanoparticles were prepared and characterized. Then, the optimized nanoparticles were loaded within inserts formulated with Methylcellulose (MC) and Polyvinyl Alcohol (PVA) by a solvent casting technique and evaluated physically, for in-vitro drug release profile. Finally, an in-vivo study was performed on the selected formulation to prove non-irritability and sustained ocular anti-inflammatory efficacy compared with free drug-loaded ocuserts. Results: The results revealed (ATC-PCL) nanoparticles prepared with 0.5% pluronic F127 were optimized with 181.72±3.6 nm particle size, 0.12±0.02 (PDI) analysis, -27.4± 0.69 mV zeta potential and 62.41%±4.7% entrapment efficiency. Nanoparticles loaded ocuserts manifested compatibility between drug and formulation polymers. Moreover, formulations complied with average weight 0.055±0.002 to 0.143±0.023 mg, and accepted pH. ATC-PCL nanoparticles loaded inserts prepared by 5% MC showed more sustained, prolonged in-vitro release over 24h. In-vivo study emphasized non-irritability, ocular anti-inflammatory effectiveness represented by smaller lid closure scores, and statistically significant lowering in PMN count after 3h. Conclusion: These findings proposed a possibly simple, new and affordable price technique to prepare promising (ATC-PCL) nanoparticles loaded inserts to achieve sustained release with prolonged antiinflammatory efficacy.


Sign in / Sign up

Export Citation Format

Share Document